Real-world outcomes of adult patients with acute lymphoblastic leukemia treated with a modified CALGB 10102 regimen
Authors:
- 1 March 2023
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 102 (4) , 897-906
Abstract
Acute lymphoblastic leukemia (ALL) is an aggressive bone marrow cancer with disparate outcomes. Data on patient outcomes in real world settings outside of clinical trials is limited. The current study reports on outcomes for 137 ALL patients who received an adult induction and consolidation regimen derived from the CALGB 10102 trial modified without alemtuzumab. Of the 137 patients, 32 were < 40 years old, 52 were between 40 and 59, and 53 were ≥ 60 years old. Overall, 109 (79.6%) patients achieved a complete remission (< 40: 96.1%, 40–59: 86.5%, and 62.3% ≥ 60 (p = 0.0002)). Progression free survival for the entire cohort was 13.5 months and by age was 19.8 months for less than 40, 23.4 months for 40 to 59 and 6.7 months for ≥ 60; p = 0.0002. Median survival was 22.1 months for the entire cohort (32.9 months for ages < 40, 26.6 months ages 40–59, 7.8 months ≥ 60, p < 0.001).Keywords
Funding Information
- NIH (1R01CA197991-01A1, P30CA012197)
This publication has 29 references indexed in Scilit:
- Dexamethasone and High-Dose Methotrexate Improve Outcome for Children and Young Adults With High-Risk B-Acute Lymphoblastic Leukemia: A Report From Children’s Oncology Group Study AALL0232Journal of Clinical Oncology, 2016
- The 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood, 2016
- Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: Results of three prospective parallel trials from the PETHEMA groupLeukemia Research, 2016
- Pediatric‐inspired therapy compared to allografting for Philadelphia chromosome‐negative adult ALL in first complete remissionAmerican Journal of Hematology, 2015
- Evaluation of comorbidity indexes in the outcome of elderly patients treated for acute lymphoblastic leukemiaLeukemia & Lymphoma, 2014
- Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st centuryBlood, 2009
- Optimal management of adults with ALLBritish Journal of Haematology, 2009
- Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemiaCancer, 2008
- A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811Blood, 1995
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987